Zota Health Care acquires 1 million shares of Curexis Ventures for Rs 2 crore

What Zota Health Care announced

Zota Health Care Limited (ticker ZOTA) informed the National Stock Exchange on 22 June 2026 that it had acquired 10,00,000 equity shares of Curexis Ventures Private Limited. The acquisition was executed by way of subscription to a right issue issued by Curexis, the company’s wholly‑owned subsidiary. The subscription price was Rs 20 per share, which includes a premium of Rs 10 per share, resulting in a total outlay of Rs 2 crore.

The filing, made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, provides a concise overview of the transaction, the target’s business, and the strategic rationale behind the move.

Details of the acquisition

• Target entity: Curexis Ventures Private Limited, incorporated on 25 February 2025, operates as a drug‑manufacturing, development and marketing company. It also runs retail pharmacy stores under the brand name SKIA, offering pharmaceutical, nutraceutical, cosmetic, Ayurvedic and OTC products.
• Shareholding: Zota already owned Curexis as a wholly‑owned subsidiary. The right‑issue subscription added 1 million shares to Zota’s existing stake, but did not alter the subsidiary status.
• Financial profile of Curexis: According to audited statements for FY 2025‑26, Curexis posted a turnover of Rs 1.18 lakhs and a paid‑up share capital of Rs 1 lakh. No turnover was reported for FY 2024‑25, and data for FY 2023‑24 is not available.
• Related‑party status: The filing confirms that the transaction does not fall within the ambit of related‑party transactions. Neither the promoters nor any promoter‑group entities hold an interest in Curexis, and the deal was executed on an arm‑length basis.
• Regulatory approvals: No governmental or other regulatory approvals were required for the acquisition.

Financial terms and consideration

The cash outflow of Rs 2 crore represents a modest investment relative to Zota’s overall balance sheet, but it is material in the context of Curexis’ limited turnover of just over Rs 1 lakh.

Why this matters for investors

• Strategic expansion: Zota cites the acquisition as part of its plan to expand the SKIA pharmacy network and to mitigate Curexis’ working‑capital requirements. By injecting fresh capital, Zota aims to strengthen the subsidiary’s operational capacity and market reach.
• Capital allocation: The transaction is a cash‑based investment rather than a share‑swap, meaning no additional dilution for Zota shareholders. The Rs 2 crore outlay will be reflected in the company’s cash‑flow statements under investing activities.
• Regulatory clarity: The filing confirms that no further approvals are pending, reducing execution risk. The arm‑length nature of the deal also removes concerns about related‑party conflicts.
• Financial impact: Given Curexis’ modest turnover, the acquisition is unlikely to have an immediate material impact on Zota’s consolidated revenue. However, the strategic intent suggests that Zota expects future growth from the SKIA retail footprint.

Conclusion

Zota Health Care Limited has completed a cash subscription of 1 million Curexis shares for Rs 2 crore, finalising the transaction on 22 June 2026. The move is positioned as a strategic investment to bolster the subsidiary’s retail pharmacy operations and address working‑capital needs. No related‑party concerns or regulatory hurdles were identified, and Curexis continues to be a wholly‑owned subsidiary of Zota. Investors should monitor subsequent disclosures for any updates on the expansion of the SKIA brand and the financial performance of Curexis in upcoming quarters.